HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy.

Abstract
The Axl receptor tyrosine kinase (RTK) has been established as a strong candidate for targeted therapy of cancer. However, the benefits of targeted therapies are limited due to acquired resistance and activation of alternative RTKs. Therefore, we asked if cancer cells are able to overcome targeted Axl therapies. Here, we demonstrate that inhibition of Axl by short interfering RNA or the tyrosine kinase inhibitor (TKI) BMS777607 induces the expression of human epidermal growth factor receptor 3 (HER3) and the neuregulin 1(NRG1)-dependent phosphorylation of HER3 in MDA-MB231 and Ovcar8 cells. Moreover, analysis of 20 Axl-expressing cancer cell lines of different tissue origin indicates a low basal phosphorylation of RAC-α serine/threonine-protein kinase (AKT) as a general requirement for HER3 activation on Axl inhibition. Consequently, phosphorylation of AKT arises as an independent biomarker for Axl treatment. Additionally, we introduce phosphorylation of HER3 as an independent pharmacodynamic biomarker for monitoring of anti-Axl therapy response. Inhibition of cell viability by BMS777607 could be rescued by NRG1-dependent activation of HER3, suggesting an escape mechanism by tumor microenvironment. The Axl-TKI MPCD84111 simultaneously blocked Axl and HER2/3 signaling and thereby prohibited HER3 feedback activation. Furthermore, dual inhibition of Axl and HER2/3 using BMS777607 and lapatinib led to a significant inhibition of cell viability in Axl-expressing MDA-MB231 and Ovcar8 cells. Therefore, we conclude that, in patient cohorts with expression of Axl and low basal activity of AKT, a combined inhibition of Axl and HER2/3 kinase would be beneficial to overcome acquired resistance to Axl-targeted therapies.
AuthorsRobert Torka, Kinga Pénzes, Simone Gusenbauer, Christine Baumann, István Szabadkai, Lászlȯ Őrfi, György Kéri, Axel Ullrich
JournalNeoplasia (New York, N.Y.) (Neoplasia) Vol. 16 Issue 4 Pg. 301-18 (Apr 2014) ISSN: 1476-5586 [Electronic] United States
PMID24862757 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 Neoplasia Press, Inc. Published by Elsevier Inc. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • GPI-Linked Proteins
  • Ligands
  • Myelin Proteins
  • Nogo Receptor 1
  • Protein Kinase Inhibitors
  • Proto-Oncogene Proteins
  • Quinazolines
  • RTN4R protein, human
  • Receptors, Cell Surface
  • Lapatinib
  • Receptor Protein-Tyrosine Kinases
  • Receptor, ErbB-2
  • Receptor, ErbB-3
  • Axl Receptor Tyrosine Kinase
Topics
  • Animals
  • Antineoplastic Agents (pharmacology)
  • Cell Line
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Drug Resistance, Neoplasm (genetics)
  • GPI-Linked Proteins (metabolism)
  • Humans
  • Lapatinib
  • Ligands
  • Mice
  • Myelin Proteins (metabolism)
  • Neoplasms (drug therapy, genetics, metabolism)
  • Nogo Receptor 1
  • Phosphorylation (drug effects)
  • Protein Binding
  • Protein Kinase Inhibitors (pharmacology)
  • Protein Multimerization (drug effects)
  • Proto-Oncogene Proteins (antagonists & inhibitors, metabolism)
  • Quinazolines (pharmacology)
  • Receptor Protein-Tyrosine Kinases (antagonists & inhibitors, metabolism)
  • Receptor, ErbB-2 (antagonists & inhibitors)
  • Receptor, ErbB-3 (chemistry, genetics, metabolism)
  • Receptors, Cell Surface (metabolism)
  • Transcription, Genetic (drug effects)
  • Transcriptional Activation
  • Triple Negative Breast Neoplasms (drug therapy, genetics, metabolism)
  • Axl Receptor Tyrosine Kinase

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: